|
|
|
Volumn 14, Issue 9, 2001, Pages 551-567
|
|
Successes and pitfalls of medicinal chemistry programs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE;
4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE;
5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE;
6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE;
6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE;
6 O CYCLOHEXYLMETHYLGUANINE;
[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;
ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;
APC 2848;
AR C118925X;
AR C126313XX;
ARC C85095MX;
BATIMASTAT;
CASPASE 3 INHIBITOR;
CYCLOOXYGENASE 2 INHIBITOR;
D 4418;
DOXAZOSIN;
GW 8547;
IMATINIB;
MARIMASTAT;
MATRIX METALLOPROTEINASE INHIBITOR;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE;
N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE;
PROTEIN KINASE INHIBITOR;
SB 257702;
SB 435466;
SB 435495;
TERAZOSIN;
UK 294315;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN RECEPTOR;
VATALANIB;
VRT 19911;
VRT 22790;
VRT 29131;
VX 702;
VX 850;
XR 11211;
CANCER;
CARDIOVASCULAR DISEASE;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL RESEARCH;
CONFERENCE PAPER;
DRUG RESEARCH;
HUMAN;
INFLAMMATION;
LIBRARY;
NONHUMAN;
PROSTATE HYPERTROPHY;
STRUCTURE ACTIVITY RELATION;
UNITED KINGDOM;
|
|
EID: 0035724597
PISSN: 02140934
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
